A South Korean Biotech Firms Gets $183.3M Funding to Build Bitcoin Treasury
Bridge Biotherapeutics, a South Korean biotech firm, is adopting a Bitcoin treasury strategy, mirroring the approach of companies like MicroStrategy (MSTR) and Metaplanet (3350). This move follows a significant 25 billion won ($183.3 million) investment from Parataxis, a crypto investment firm. The partnership will see Bridge rebrand as Parataxis Korea, while maintaining its KOSDAQ listing.
This strategic shift is driven by the increasing global interest in Bitcoin treasury strategies, as highlighted by Parataxis partner Andrew Kim. The success of companies like MicroStrategy, holding over 2.8% of all potential Bitcoin, and Metaplanet, possessing 10,000 BTC (approximately $1.04 billion), demonstrates the potential for significant share price appreciation through Bitcoin exposure. These companies have attracted investors seeking Bitcoin exposure without directly holding the cryptocurrency.
Bridge’s adoption of this strategy positions it alongside other healthcare-related companies, Semler Scientific (SMLR) and Prenetics Global (PRE), who have also embraced Bitcoin treasuries. This trend indicates a growing acceptance of Bitcoin as a strategic asset within diverse sectors. The partnership further strengthens Parataxis’s profile; the firm is preparing for a US public listing via a SPAC, SilverBox Corp IV (SBXD).
The market reacted positively to the announcement, with Bridge shares closing over 20.5% higher on Friday, reaching 943 won ($0.69). This significant increase reflects investor confidence in the strategy and the potential for future growth. The move by Bridge Biotherapeutics underscores the expanding global adoption of Bitcoin as a treasury asset and its impact on corporate strategies across various industries. The collaboration with Parataxis, a firm actively engaging in the US capital markets, positions Bridge for further international exposure and growth. This case study highlights the potential for synergistic growth between the biotech sector and cryptocurrency investment strategies. The strategic partnership represents a significant development in the convergence of traditional finance and the cryptocurrency market in South Korea.
